Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.48), $0.29 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $8.73 million versus the consensus estimate of $10.26 million.

“In 2019, we achieved continued growth in our XERMELO (telotristat ethyl) business of nearly 25% year-over-year and made significant strides in advancing pipeline initiatives such as telotristat ethyl in biliary tract cancer and LX9211 in neuropathic pain,” said Lonnel Coats, Lexicon’s president and chief executive officer. “We expect initial clinical efficacy data for telotristat ethyl in biliary tract cancer by the end of this year. As for LX9211, we are initiating a proof-of-concept study in diabetic peripheral neuropathic pain in the first half of this year.”

“We received a response yesterday from the Center for Drug Evaluation and Research (CDER) to our appeal of the FDA’s complete response letter (CRL) for sotagliflozin in type 1 diabetes,” continued Mr. Coats. “The response confirmed the CRL decision, and we are now evaluating the feedback they provided in their response."

“We are engaged in discussions around potential partnerships for sotagliflozin, which will be necessary to enable completion of the long-term outcomes studies, SCORED and SOLOIST, that are designed to demonstrate benefits in and support labeling for heart failure and chronic kidney disease.”

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.